Topic
Drug carrier
About: Drug carrier is a research topic. Over the lifetime, 18276 publications have been published within this topic receiving 997718 citations. The topic is also known as: drug carriers & drug vehicle.
Papers published on a yearly basis
Papers
More filters
TL;DR: The potential applications of liposomes in drug delivery with examples of formulations approved for clinical use are discussed, and the problems associated with further exploitation of this drug delivery system are discussed.
1,108 citations
TL;DR: This article provides a review of this field with respect to methods of particle preparation and the role of particle shape in drug delivery.
1,081 citations
TL;DR: Intravenously injected doxorubicin-loaded polysorbate 80-coated nanoparticles were able to lead to a 40% cure in rats with intracranially transplanted glioblastomas 101/8, and may be especially helpful for the treatment of the disseminated and very aggressive brain tumors.
1,073 citations
1,068 citations
TL;DR: The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endolysosomal compartment, which causes the NPs to interact with the endo‐lysosomal membrane and escape into the cytosol.
Abstract: The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation. Current vectors that enable the endo-lysosomal escape of macromolecules such as DNA are limited by their toxicity and by their ability to carry only limited classes of therapeutic agents. In this paper, we report the rapid (<10 min) endo-lysosomal escape of biodegradable nanoparticles (NPs) formulated from the copolymers of poly(DL-lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endo-lysosomal compartment, which causes the NPs to interact with the endo-lysosomal membrane and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic agents, including macromolecules such as DNA and low molecular weight drugs such as dexamethasone, intracellularly at a slow rate, which results in a sustained therapeutic effect. PLGA has a number of advantages over other polymers used in drug and gene delivery including biodegradability, biocompatibility, and approval for human use granted by the U.S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules.
1,031 citations